Stem Cells Push Back

The habit of putting handcuffs on human embryonic stem cell research might soon become a thing of the past, two news items point out today. Federal lawmakers want to get rid of three patents related to human embryonic stem cells, which could ease restrictions on future commercialization.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.